July 23 (Reuters) - Eli Lilly and Co said its quarterly revenue rose about 1 percent, helped by demand for its new cancer and diabetes treatments and the acquisition of Novartis AG's animal health business.

The Indianapolis-based drugmaker's net profit fell to $600.8 million, or 56 cents per share, in the second quarter ended June 30, from $733.5 million, or 68 cents per share, a year earlier.

Revenue rose to $4.98 billion from $4.94 billion.

(Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)